Database Query Results : , , TRAF1

TRAF1, TNF Receptor–Associated Factor 1: Click to Expand ⟱
Source:
Type:
TRAF1 is an adaptor protein in TNF receptor superfamily signaling that modulates NF-κB, MAPK, and apoptotic pathways. Unlike other TRAFs, TRAF1 lacks intrinsic E3 ubiquitin ligase activity, acting instead as a regulatory scaffold. In cancer, TRAF1 is best viewed as a pro-survival, anti-apoptotic signal amplifier, especially in immune-related and hematologic malignancies.
Expression Pattern in Cancer
-Low or absent in most normal tissues
-Inducible by NF-κB
-Overexpressed in many cancers, especially:
  -B-cell lymphomas (CLL, Hodgkin lymphoma, DLBCL)
  -Multiple myeloma
  -Some solid tumors with inflammatory microenvironments
-High TRAF1 expression correlates with:
-Therapy resistance
-Immune-evasive phenotypes
-Poor prognosis (context-dependent)


Scientific Papers found: Click to Expand⟱
5150- GamB,    Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway
- in-vitro, CLL, KBM-5 - in-vitro, Nor, HEK293
Apoptosis↑, ChemoSen↑, IAP1↓, IAP2↓, Bcl-2↓, Bcl-xL↓, TRAF1↓, cycD1/CCND1↓, cMyc↓, COX2↓, MMP9↓, angioG↓, VEGF↓, NF-kB↓, eff↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   IAP1↓, 1,   IAP2↓, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,  

Migration ⓘ

MMP9↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   NF-kB↓, 1,   TRAF1↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↓, 1,  
Total Targets: 15

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TRAF1, TNF Receptor–Associated Factor 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1437  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page